Background. Effective treatment for enzalutamide-resistant prostate cancer is an unmet need. The LREX' prostate cancer model is resistant to the antiandrogen enzalutamide via activation of an alternative nuclear receptor, glucocorticoid receptor, which has similar DNA binding specificity to the androgen receptor. Furthermore, glucocorticoid receptor expression in mCRPC associates with poor response to enzalutamide. Small molecules that target DNA to interfere with protein-DNA interactions may retain activity against enzalutamide-resistant prostate cancers where ligand binding domain antagonists are ineffective. Pyrrole-Imidazole (Py-Im) polyamides are minor groove-binding small molecules with high affinity and programmable sequence specificity. We hypothesized that ARE-1, a polyamide targeted to the androgen receptor response element half-site, may be effective against enzalutamide-resistant prostate cancer in cell and animal models.
